Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

7.11USD
11:43am EDT
Price Change (% chg)

$-1.40 (-16.45%)
Prev Close
$8.51
Open
$7.13
Day's High
$7.38
Day's Low
$7.00
Volume
566,080
Avg. Vol
359,862
52-wk High
$9.10
52-wk Low
$3.86

HALO.OQ

Chart for HALO.OQ

About

Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix. The Company’s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a... (more)

Overall

Beta: 1.63
Market Cap (Mil.): $962.68
Shares Outstanding (Mil.): 113.12
Dividend: --
Yield (%): --

Financials

  HALO.OQ Industry Sector
P/E (TTM): -- 14.86 16.01
EPS (TTM): -0.51 -- --
ROI: -53.66 7.49 15.63
ROE: -102.40 12.26 19.20
Search Stocks

UPDATE 1-Halozyme drug delivery technology in doubt after trial halted

* Says partner ViroPharma halts trial after unexpected antibody production

10:47am EDT

BRIEF-Halozyme Therapeutics shares up 27 pct in heavy volume

NEW YORK, March 22 - Halozyme Therapeutics Inc : * Shares extend advance in heavy volume, up 27 percent

22 Mar 2013

Competitors

  Price Change
Novo Nordisk A/S (NOVOb.CO) kr.975.00 +27.00
Sanofi SA (SASY.PA) €76.85 -3.32
Eli Lilly & Co. (LLY.N) $53.30 +0.19
MannKind Corporation (MNKD.OQ) $8.12 +0.40
Biodel Inc (BIOD.OQ) $4.97 +0.06

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Quantitative Report
$69.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks